IDEXX Laboratories, Inc. $IDXX Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,221 shares of the company’s stock after selling 2,673 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in IDEXX Laboratories were worth $14,733,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $26,000. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories in the 2nd quarter worth about $30,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on IDXX shares. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Stock Down 2.0%

Shares of NASDAQ:IDXX opened at $552.46 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $43.58 billion, a P/E ratio of 40.68, a P/E/G ratio of 3.08 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98. The stock’s fifty day simple moving average is $555.50 and its 200-day simple moving average is $597.62.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the business posted $2.91 EPS. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.